Transcat, Inc. · NASDAQ:TRNS
Transcat — Investor Presentation (September 2026)
31 slides from Transcat's investor presentation, September 2026
Slide 1: Leader in Test, Measurement, Control & Calibration
NASDAQ: TRNS Leader in Test, Measurement, Control & Calibration INVESTOR PRESENTATION September 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than historical fact are forward-looking statements. Forward-looking statements are not statements of historical fact and thus
Slide 3: Corporate Overview & Strategy
Corporate Overview & Strategy Transcat is an industry leading provider of mission critical, accredited calibration services and equipment, and the only public company of its kind. Highly fragmented, large market opportunity highlights NASDAQ: TRNS path to $500M revenue and top-tier margins in 3-5 ye
Slide 4: Company Overview
Company Overview Industry leading provider of mission critical, accredited calibration services and equipment FOUNDED IN 1964 NASDAQ:TRNS DISTRIBUTOR AND FOOTPRINT 35 COMMERCIAL 69 CONSECUTIVE TRANSCAT NEXA COST, OVER 62 YEARS PUBLICLY-TRADED RENTAL OF TEST AND SCALE TO LABS QUARTERS OF YOY UNIVERSI
Slide 5: Compelling Equity Story with Multiple Growth Drivers
Compelling Equity Story with Multiple Growth Drivers Industry Transcat Strong and Attractive Fundamentals Wide and expanding moat Flywheel of complimentary Growing TAM Attractive & Growing Market leading Footprint 1 & technical expertise 2 businesses End Markets Global leader in providing full-servi
Slide 6: Consistent performance, evolving model
Consistent performance, evolving model We have transformed into high margin, recurring revenue, services company 2012A REVENUE BY SEGMENT TTM JUN-26 REVENUE BY SEGMENT 33% 34% Transcat’s management team strategically ~$110M focused on improving recurring revenue, with ~$348M the Service segment grow
Slide 7: Strategic, Regulated, Growing Vertical Markets
Strategic, Regulated, Growing Vertical Markets • Provider of premium, mission critical services to regulated, high cost of failure industries that require long qualification cycles • High switching costs deeply entrench customers on Transcat service platform; high barrier to entry that results in re
Slide 8: Market leading footprint & technical expertise
Market leading footprint & technical expertise • 50+ Locations U.S., Canada, Ireland & Latin America • Mobile lab capabilities for speed and flexibility • Deep technical talent and leading calibration breadth Map Legend Transcat Headquarters Transcat Calibration Labs Transcat Client-Based Lab (CBL)
Slide 9: Flywheel of complimentary businesses
Flywheel of complimentary businesses Strong cross-selling opportunities from distribution to calibration services OPPORTUNITY FOR ACCELERATED GROWTH AND MARGIN EXPANSION nu e ws Su e Pr Flo pp ev i sh m R or a ar g gC ts rin yG Gro S t r on Recur r ow t h D r i v e r wth S trateg Calibration Service
Slide 10: Blue-Chip Customer Base
Blue-Chip Customer Base Servicing Fortune 500 Manufacturers Percentage of Service Revenue 1 Life Science / FDA Regulated, 60% Industrials / Materials, 16% Aerospace / Defense, 8% Services / Consumer Goods, 7% Energy / Utilities, Other, 4% 5% 1. * Company estimates based on FY 2025 10
Slide 11: Acquirer of choice in a fragmented market
Acquirer of choice in a fragmented market Increased Capabilities Leveraged Infrastructure Year Target Geographic Expansion & Expertise (Bolt-on) FY27 FY27 FY25 FY25 FY24 FY24 FY24 FY24 FY23 FY22 FY22 FY22 FY21 FY21 * Company estimates based on FY 2025 11
Slide 12: Acquisition & Integration Strategy
Acquisition & Integration Strategy Proven Process Drives Consistent Long-Term Value Capture and Returns Diligence & Decision Making Martin Calibration – Case Study • Disciplined approach with high emphasis on cultural fit Expanding Presence in Upper Midwest • Strategic checklist and consistent asses
Slide 13: Essco Calibration Laboratory
Essco Calibration Laboratory New England Market Leader in Calibration Services ✓ Largest deal in Transcat history - $84 million cash purchase – August 2025 ✓ Transaction was supported by new $150 million syndicated credit facility jointly led by M&T Bank and Wells Fargo Bank ✓ Operating for over 50
Slide 14: SCM Metrology & Laboratories S.A.
SCM Metrology & Laboratories S.A. Opportunity-Rich Latin American Market with Strategically Aligned Customers ✓ $13 million cash purchase – April 2026 ✓ First operational presence in Latin America, advancing the strategy to grow alongside customers in high-growth, highly regulated end markets ✓ Oper
Slide 15: Southeastern Biomedical Associates Inc.
Southeastern Biomedical Associates Inc. Expands Biomedical Calibration Channel Throughout the Southeastern United States ✓ $12.8 million cash purchase – August 2026 ✓ Expands accredited biomedical calibration capabilities, equipment repair, and preventative maintenance services ✓ Extends Transcat's
Slide 16: 69 consecutive quarters of YoY Service Growth
69 consecutive quarters of YoY Service Growth Acquires SCM Metrology and Laboratories S.A. & Southeastern Biomedical Associates Inc. GM% 1) Shift to Service drives Acquires Martin Calibration & Essco Calibration Laboratory 35% accelerated growth Axiom 275,000 Accelerating Rental Growth 2) Service Ma
Slide 17: Our Vision is to be as well known for operational excellence
Our Vision is to be as well known for operational excellence as we have been for growth Transcat’s Four-Pillar Strategy Organic Calibration Mergers & Rentals Calibration Margin % Acquisitions Growth Growth Expansion + 13% FY27 Q1 organic +90 bps FY27 Q1 services Added SCM (Costa Rica), 10% FY27 Q1 g
Slide 18: Q1 FY27 Summary
Q1 FY27 Summary • Q1 Revenue grew 22% vs prior year to $92.9M • Q1 Net Income of $1.3M or $0.14 per diluted share Consolidated Results • Adjusted EBITDA* increased 19% from prior year to $14.0M in Q1 • Adjusted Diluted EPS* of $0.51 • Service Revenue increased 27% in Q1 to $62.6M • Service Organic R
Slide 19: Outlook
Outlook* 2027 Expectations Service segment: For fiscal 2027, we expect Service organic revenue growth in the high single-digits and Service gross margin expansion, assuming a stable economic environment Mid-to-long Term Outlook • Highly fragmented, large market opportunity highlights path to $500M r
Slide 20: Summary
Summary • 62 years experience across complementary Calibration Services and Distribution/Rental segments in an attractive market with strong fundamentals • Market leadership position with a strong and expanding moat in highly regulated, high cost of failure, and mission critical industries including
Slide 21: Investor Relations
NASDAQ: TRNS Investor Relations Chris Tyson Executive Vice President MZ Group - MZ North America 949-491-8235 TRNS@mzgroup.us TRANSCAT, INC transcat.com transcat.com 35 Vantage Point Drive Rochester, NY 14624
Slide 22: Financial Overview
Financial Overview
Slide 23: Revenue
Revenue ($ in millions) Service Segment Distribution Segment Consolidated $62.6 $92.9 $30.4 $27.3 $76.4 $49.1 27% 11% 22% Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 • Consolidated Q1 revenue up 21.6%, with both segments Full Year Consolidated delivering double-digit growth $331.9 • Service reve
Slide 24: Gross Profit and Margin
Gross Profit and Margin ($ in millions) Service Segment Distribution Segment Consolidated $21.2 $9.6 $30.7 31% $9.6 (0.6%) 19% $16.2 $25.8 33.0% 33.9% 35.2% 31.4% 33.8% 33.1% Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 • Consolidated Gross Profit of $30.7M for Q1 increased 19% Full Year Consolid
Slide 25: Net Income, Diluted EPS, Adjusted Diluted EPS
Net Income, Diluted EPS, Adjusted Diluted EPS* ($ in millions, except EPS) Net Income Diluted EPS Adjusted Diluted EPS* $3.3 $0.35 (59%) (60%) $0.59 (14%) $0.51 $1.3 $0.14 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Full Year Net Income • Q1 adjusted diluted EPS of $0.51 vs $0.59 prior year $14.
Slide 26: Adjusted Operating Income, EBITDA and Margin
Adjusted Operating Income*, EBITDA* and Margin ($ in millions) Service Adjusted Distribution Adjusted Consolidated Adjusted Operating Income* Operating Income* EBITDA* $14.0 $9.6 $4.9 35% (12%) $4.3 $11.8 19% $7.2 14.6% 15.4% 18.1% 14.3% 15.4% 15.0% Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Fu
Slide 27: Operating Free Cash Flow
Operating Free Cash Flow ($ in millions) Three Months Ended Note: Components may not add to totals June 27, 2026 June 28, 2025 • Operating Free Cash Flow** of $4.8M for Q1 due to rounding reflects higher cash from operations and slightly lower capital expenditures Net cash provided by operations $8.
Slide 28: Balance Sheet Supports Growth Strategy
Balance Sheet Supports Growth Strategy ($ in millions) Capitalization Note: Components may not add to totals due to rounding June 27, 2026 March 28, 2026 Cash & Cash Equivalents $6.7 $4.9 • 2.21x leverage ratio at quarter-end (Total debt to TTM Adjusted Total Debt $110.4 $99.9 EBITDA*) Total net deb
Slide 29: Supplemental Information
Supplemental Information
Slide 30: Adjusted EBITDA and Operating Income Reconciliation
Adjusted EBITDA and Operating Income Reconciliation ($ in thousands) FY 2027 Q1 FY 2026 Q1 Net Income $ 1,331 $ 3,261 ($ in thousands) + Interest Expense, net 1,515 440 + Tax Provision 854 1,304 + Depreciation & Amortization 6,914 5,605 + Executive Transition Costs 736 - + Transaction Expense 628 28
Slide 31: Adjusted Diluted EPS Reconciliation
Adjusted Diluted EPS Reconciliation ($ in thousands) ($ in thousands except per share data) FY 27 Q1 FY 26 Q1 GAAP Net Income $ 1,331 $ 3,261 Add back (deduct) $ 3,521 $ 2,263 Amortization of Intangibles 3,598 2,844 Transaction Expense 628 28 Acq Stock Expense 186 145 Executive Transition Costs 736